About us
Consortium partners
Current partners
Merck (Germany) leads the program. Expert in praziquantel, it provides resources and support from different areas: pre-clinical, clinical, manufacturing, regulatory and access. It was responsible for the clinical development program and sponsored the clinical trials. Together with partners, Merck prepares the new access path.
Astellas Pharma Inc. (Japan) has developed the new pediatric praziquantel formulations, and provides expert advice on clinical development in children, and pharmacokinetic modeling.
Swiss Tropical and Public Health Institute (Switzerland) is a not-for-profit Institute internationally renowned for its research, services, teaching and training in global health. It contributes with extensive experience in helminths biological and pharmacological research; epidemiology; and clinical research in endemic regions.
Lygature (The Netherlands), a not-for-profit foundation, acts as the independent coordinator of the Consortium, providing governance in terms of progress, finance and collaboration. Since 2006, Lygature has supported close to a hundred public-private partnerships in the field of life sciences & health, including poverty-related diseases.
Farmanguinhos (Brazil), the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to addressing the production and distribution of new pediatric formulations in endemic countries.
Unlimit Health (United Kingdom) is an international organization working to end parasitic disease. They partner with ministries of health to develop country-owned solutions that eliminate preventable infections. This work strengthens health systems, so people can live healthy lives, free from limiting disease.
Kenya Medical Research Institute (Kenya), provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the conduct of the trials in Kenya according to Good Clinical Practice and national and local regulatory and ethics standards.
Université Félix Houphouët-Boigny (Côte d’Ivoire) was previously involved in the phase II clinical trials of the pediatric praziquantel formulation. It provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the phase III trials in Côte d’Ivoire according to Good Clinical Practice and national and local regulatory and ethics standards.
Technischen Universität München (Germany) represented by the Center for Global Health and the Department of Neurology provides multi- and interdisciplinary expertise and partnership in the field of Neglected Tropical Diseases in several countries of the Global South.
The African Institute for Health and Development (Kenya) is a non-profit, non-governmental organization established in 2004 in Kenya. The Institute’s main focus is on implementing evidence-based programming, conducting research, training and advocacy on development issues that are contextually relevant to Kenya and the African continent as a whole. In partnership with the National and County governments in Kenya, and working with local, national, regional and international partners, the AIHD has the mission of working with communities for better lives.
Ministry of Health, Côte d’Ivoire. The National Programme for the Control of Neglected Tropical Diseases (NTDs) through Preventive Chemotherapy (PNLMTN-CP) was established by the Ministry of Health in Côte d’Ivoire and provides leadership and coordination of all the partners and stakeholders involved in the fight against NTDs. Emphasis is placed on the activities demonstrating large reduction in morbidity and mortality associated with these infections.
Supported by
The Ministry of Health in Kenya, represented by the Division of Vector Borne and Neglected Tropical Diseases provides equitable, affordable, accessible and quality health care for all by building a progressive, responsive and sustainable health care system for accelerated attainment of the highest standard of health to all Kenyans.
Ministry of Health, Uganda. The Vector Borne and Neglected Tropical Diseases (VB&NTDs) Division, part of the Ministry of Health in Uganda, is mandated to control and eliminate all vector borne diseases including mosquito borne diseases, schistosomiasis, onchocerciasis, lymphatic filariasis, human trypanosomiasis, leishmaniasis, plague and louse borne typhi in Uganda. In addition, VB&NTDs play the role of a centre for research on all the above vector borne diseases, including malaria and intestinal worms.
Makerere University School of Public Health (Uganda) is committed to building its research capacity as a way to address public health challenges by conducting population-based and other types of research, next to the evaluation of health programs and health systems. To support the planning, implementation and evaluation of health programmes, MakSPH collaborates closely with the Ugandan Ministry of Health.